Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1990 1
1991 3
1996 1
1997 2
1998 2
1999 4
2000 3
2001 1
2002 1
2003 4
2004 1
2005 2
2006 5
2007 9
2008 7
2009 1
2010 3
2011 4
2012 4
2013 5
2014 6
2015 1
2016 3
2017 6
2018 1
2019 5
2020 4
2021 2
2022 1
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Results by year

Filters applied: . Clear all
Page 1
Sinz M. Sinz M. Curr Drug Metab. 2019;20(1):2. doi: 10.2174/138920022001190125110659. Curr Drug Metab. 2019. PMID: 30887914 No abstract available.
Sinz MW. Sinz MW. Curr Drug Metab. 2017;18(1):1. doi: 10.2174/138920021801170119202545. Curr Drug Metab. 2017. PMID: 28889795 No abstract available.
Cytochrome P450 reaction-phenotyping: an industrial perspective.
Zhang H, Davis CD, Sinz MW, Rodrigues AD. Zhang H, et al. Among authors: sinz mw. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):667-87. doi: 10.1517/17425255.3.5.667. Expert Opin Drug Metab Toxicol. 2007. PMID: 17916054 Review.
Metabolomic Profiling and Drug Interaction Characterization Reveal Riboflavin As a Breast Cancer Resistance Protein-Specific Endogenous Biomarker That Demonstrates Prediction of Transporter Activity In Vivo.
Zhang Y, Shipkova PA, Warrack BM, Nelson DM, Wang L, Huo R, Chen J, Panfen E, Chen XQ, Fancher RM, Ruan Q, Christopher LJ, Xue Y, Sinz M, Shen H. Zhang Y, et al. Among authors: sinz m. Drug Metab Dispos. 2023 Jul;51(7):851-861. doi: 10.1124/dmd.123.001284. Epub 2023 Apr 13. Drug Metab Dispos. 2023. PMID: 37055191
Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions-an Industry Perspective.
Bohnert T, Patel A, Templeton I, Chen Y, Lu C, Lai G, Leung L, Tse S, Einolf HJ, Wang YH, Sinz M, Stearns R, Walsky R, Geng W, Sudsakorn S, Moore D, He L, Wahlstrom J, Keirns J, Narayanan R, Lang D, Yang X; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) Victim Drug-Drug Interactions Working Group. Bohnert T, et al. Among authors: sinz m. Drug Metab Dispos. 2016 Aug;44(8):1399-423. doi: 10.1124/dmd.115.069096. Epub 2016 Apr 6. Drug Metab Dispos. 2016. PMID: 27052879 Review.
Synthesis and biological evaluation of biaryl alkyl ethers as inhibitors of IDO1.
Markwalder JA, Balog AJ, Williams DK, Nara SJ, Reddy R, Roy S, Kanyaboina Y, Li X, Johnston K, Fan Y, Lewis H, Marsilio F, Yan C, Critton D, Newitt JA, Traeger SC, Wu DR, Jure-Kunkel MN, Jayaraman L, Lin TA, Sinz MW, Hunt JT, Seitz SP. Markwalder JA, et al. Among authors: sinz mw. Bioorg Med Chem Lett. 2023 May 15;88:129280. doi: 10.1016/j.bmcl.2023.129280. Epub 2023 Apr 11. Bioorg Med Chem Lett. 2023. PMID: 37054759
Development of BET Inhibitors as Potential Treatments for Cancer: Optimization of Pharmacokinetic Properties.
Hill MD, Fang H, Norris D, Delucca GV, Huang H, DeBenedetto M, Quesnelle C, Schmitz WD, Tokarski JS, Sheriff S, Yan C, Fanslau C, Haarhoff Z, Huang C, Kramer M, Madari S, Menard K, Monereau L, Morrison J, Raghavan N, Shields EE, Simmermacher-Mayer J, Sinz M, Tye CK, Westhouse R, Xie C, Zhang H, Zhang L, Zvyaga T, Lee F, Gavai AV, Degnan AP. Hill MD, et al. Among authors: sinz m. ACS Med Chem Lett. 2022 Jul 5;13(7):1165-1171. doi: 10.1021/acsmedchemlett.2c00219. eCollection 2022 Jul 14. ACS Med Chem Lett. 2022. PMID: 35859878 Free PMC article.
89 results